ResearcherLMU KlinikumActive in the last 2 years
Danmei Zhang
Matched on ORCID iD 0000-0001-6048-4711; OpenAlex author ID A5055487140. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 40
2023: 5 papers · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper
Papers 9
- Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreatic cancer. Co-author DOI 10.1016/j.ejca.2026.117040↗
- Author Correction: Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Co-author DOI 10.1038/s41586-025-08979-z↗
- Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection? Co-author DOI 10.1007/s12094-023-03323-1↗
- Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial. Co-author DOI 10.1016/j.ejca.2024.113926↗
- Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison … Co-author DOI 10.1007/s00432-022-04112-z↗
- Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. First author DOI 10.1007/s11523-023-00950-0↗
- Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Co-author DOI 10.1038/s41586-023-05728-y↗
- Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrospective Cohort Study. Co-author DOI 10.1159/000528722↗
- Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pan… Co-author DOI 10.3390/curroncol30060436↗
Closest collaborators
The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Stefan Hubert Boeck · 9 shared papers, 2023–2026 · strength 1.50
- Paper Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreati… DOI 10.1016/j.ejca.2026.117040↗
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Author Correction: Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. DOI 10.1038/s41586-025-08979-z↗
- Volker Heinemann · 7 shared papers, 2023–2026 · strength 1.21
- Paper Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreati… DOI 10.1016/j.ejca.2026.117040↗
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
- Michael Haas · 6 shared papers, 2023–2024 · strength 0.92
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
- Paper Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrosp… DOI 10.1159/000528722↗
- Klara Dorman · 6 shared papers, 2023–2024 · strength 0.92
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
- Paper Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrosp… DOI 10.1159/000528722↗
- Lena Weiss · 5 shared papers, 2023–2024 · strength 0.78
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
- Paper Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrosp… DOI 10.1159/000528722↗
- Christoph Benedikt Westphalen · 5 shared papers, 2023–2024 · strength 0.78
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
- Paper Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrosp… DOI 10.1159/000528722↗
- Steffen Ormanns · 4 shared papers, 2023–2026 · strength 0.72
- Paper Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreati… DOI 10.1016/j.ejca.2026.117040↗
- Paper Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrosp… DOI 10.1159/000528722↗
- Paper Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IF… DOI 10.1007/s00432-022-04112-z↗
- Jens Thomas Siveke · 4 shared papers, 2023–2025 · strength 0.59
- Paper Author Correction: Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. DOI 10.1038/s41586-025-08979-z↗
- Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
- Paper Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for As… DOI 10.3390/curroncol30060436↗
- Michael Guenther · 2 shared papers, 2023–2026 · strength 0.43
- Paper Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreati… DOI 10.1016/j.ejca.2026.117040↗
- Paper Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IF… DOI 10.1007/s00432-022-04112-z↗
- Julia V. Mayerle · 3 shared papers, 2023–2024 · strength 0.43
- Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
- Paper Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for As… DOI 10.3390/curroncol30060436↗
- Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
- Volker Kunzmann · 2 shared papers, 2023–2026 · strength 0.43
- Paper Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreati… DOI 10.1016/j.ejca.2026.117040↗
- Paper Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for As… DOI 10.3390/curroncol30060436↗
- Dirk Waldschmidt · 2 shared papers, 2024 · strength 0.35
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
- Kathrin Heinrich · 2 shared papers, 2023–2024 · strength 0.32
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
- Anke Reinacher‐Schick · 2 shared papers, 2023–2024 · strength 0.30
- Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
- Paper Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for As… DOI 10.3390/curroncol30060436↗
- Stephan Krüger · 2 shared papers, 2023 · strength 0.30
- Paper Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrosp… DOI 10.1159/000528722↗
- Paper Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IF… DOI 10.1007/s00432-022-04112-z↗
- Leonie Konczalla · 2 shared papers, 2023–2025 · strength 0.29
- Nicola Gagliani · 2 shared papers, 2023–2025 · strength 0.29
- Marija Trajkovic‐Arsic · 2 shared papers, 2023–2025 · strength 0.29
- Marianne Sinn · 2 shared papers, 2023–2025 · strength 0.29
- Joseph Tintelnot · 2 shared papers, 2023–2025 · strength 0.29
- Alec C. Kimmelman · 2 shared papers, 2023–2025 · strength 0.29
- Jakob Robert Izbicki · 2 shared papers, 2023–2025 · strength 0.29
- Cenap Güngör · 2 shared papers, 2023–2025 · strength 0.29
- Faik Güntac Uzunoglu · 2 shared papers, 2023–2025 · strength 0.29
- Sai Agash Surendran · 1 shared paper, 2026 · strength 0.29
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.